Category Press Releases

Propel Health Appoints Amy Koch as Senior Vice President, Client Services in Medical Affairs

Amy Koch Joins Propel Health Medical Affairs as Senior Vice President, Client Services Propel Health Medical Affairs (PHMA), a full-service scientific communications agency operating within the broader Propel Health ecosystem, has announced the appointment of Amy Koch as Senior Vice…

Read MorePropel Health Appoints Amy Koch as Senior Vice President, Client Services in Medical Affairs

Glaukos to Showcase Multiple Scientific Abstracts at the 2026 ASCRS Annual Meeting

Glaukos to Showcase Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting Glaukos Corporation (NYSE: GKOS), a leading innovator in ophthalmic pharmaceuticals and medical devices, has announced its prominent participation in the upcoming American…

Read MoreGlaukos to Showcase Multiple Scientific Abstracts at the 2026 ASCRS Annual Meeting

Allevion Medical™ Secures 510(k) Clearance for Vantage™, an Innovative Fully Disposable System for Spinal Decompression

Allevion Medical™ Secures 510(k) Clearance for Vantage™, an Innovative Fully Disposable System Designed for Advanced Spinal Decompression Allevion Medical has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its latest innovation, Vantage™, a…

Read MoreAllevion Medical™ Secures 510(k) Clearance for Vantage™, an Innovative Fully Disposable System for Spinal Decompression
Coya Therapeutics

Coya Therapeutics Unveils Board Transition Plan, Appoints Mark H. Pavao as Independent Director

Coya Therapeutics Details Upcoming Board Transition, Names Mark H. Pavao as Independent Director Coya Therapeutics, Inc., a clinical-stage biotechnology company focused on developing innovative biologic therapies designed to enhance regulatory T cell (Treg) function in patients with neurodegenerative diseases, has…

Read MoreCoya Therapeutics Unveils Board Transition Plan, Appoints Mark H. Pavao as Independent Director

INLEXZO™ Granted Permanent Billing Code to Expand Access for Select Bladder Cancer Patients

INLEXZO™ (gemcitabine intravesical system) Receives Permanent Billing Code to Enhance Access for Select Bladder Cancer Patients Johnson & Johnson has announced a key reimbursement milestone for its bladder cancer therapy INLEXZO, with the assignment of a permanent Healthcare Common Procedure…

Read MoreINLEXZO™ Granted Permanent Billing Code to Expand Access for Select Bladder Cancer Patients

Janux Therapeutics Names New Candidate in Bristol Myers Squibb Collaboration, Triggers $35M Milestone

Janux Therapeutics Confirms Candidate Nomination in Bristol Myers Squibb Partnership, Activating $35 Million Milestone Payment Janux Therapeutics, Inc. has announced a significant milestone under its strategic collaboration with Bristol Myers Squibb, marking continued progress in the development of next-generation immunotherapies.…

Read MoreJanux Therapeutics Names New Candidate in Bristol Myers Squibb Collaboration, Triggers $35M Milestone